We are live on ! Find out more
MOLN icon

Molecular Partners

7 hedge funds and large institutions have $13.9M invested in Molecular Partners in 2026 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more funds holding

Funds holding: 5 → 7 (+2)

0.21% less ownership

Funds ownership: 9.58% → 9.37% (-0.21%)

99% less capital inflows, than outflows

Capital inflows: $248 | Capital outflows: $20.4K

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
7
Holders Change
+2
Holders Change %
+40%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$186
2
JP Morgan Chase
JP Morgan Chase
New York
+$62

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$19.8K
2
UBS Group
UBS Group
Switzerland
-$529

MOLN Hedge Fund Activity: Q3 2026 in Review

7 of the 8,184 institutional investors tracked by Wall St. Rank reported a position in Molecular Partners (MOLN) for Q3 2026, worth a combined $13.9M — up 0.81% from $13.8M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new MOLN positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $186. The largest seller was Citadel Advisors, cutting an estimated $19.8K.

  • 7 institutional investors held Molecular Partners (MOLN) as of Q3 2026, up from 5 in Q2 2026.
  • Funds reported $13.9M of Molecular Partners stock for Q3 2026, up 0.81% quarter-over-quarter.
  • 2 funds opened new Molecular Partners positions in Q3 2026 and 0 closed out, a net change of +2 holders.
  • The largest Molecular Partners buyer in Q3 2026 was Tower Research Capital (TRC), an estimated $186 added.
  • The largest Molecular Partners seller in Q3 2026 was Citadel Advisors, an estimated $19.8K sold.

Based on aggregated 13F filings for Q3 2026.